By a News Reporter-Staff News Editor at Clinical Trials Week -- Research findings on Clinical Research are discussed in a new report. According to news originating from Pasadena, California, by NewsRx correspondents, research stated, "Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function in humans is difficult to obtain, animal studies that can be correlative to human behavior are needed to provide guidance for human clinical trials."
Our news journalists obtained a quote from the research from the California Institute of Technology, "Here, we report correlative studies on animals and humans for CRLX101, a 20- to 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 is currently in phase 2 clinical trials, and human data from several of the clinical investigations are compared with results from multispecies animal studies. The pharmacokinetics of polymer-conjugated CPT (indicative of the CRLX101 nanoparticles) in mice, rats, dogs, and humans reveal that the area under the curve scales linearly with milligrams of CPT per square meter for all species. Plasma concentrations of unconjugated CPT released from CRLX101 in animals and humans are consistent with each other after accounting for differences in serum albumin binding of CPT. Urinary excretion of polymer-conjugated CPT occurs primarily within the initial 24 h after dosing in animals and humans. The urinary excretion dynamics of polymer-conjugated and unconjugated CPT appear similar between animals and humans. CRLX101 accumulates into solid tumors and releases CPT over a period of several days to give inhibition of its target in animal xenograft models of cancer and in the tumors of humans."
According to the news editors, the research concluded: "Taken in total, the evidence provided from animal models on the CRLX101 mechanism of action suggests that the behavior of CRLX101 in animals is translatable to humans."
For more information on this research see: Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proceedings of the National Academy of Sciences of the United States of America, 2013;110(37):15127-15132. Proceedings of the National Academy of Sciences of the United States of America can be contacted at: Natl Acad Sciences, 2101 Constitution Ave NW, Washington, DC 20418, USA. (National Academy of Sciences - www.nasonline.org/; Proceedings of the National Academy of Sciences of the United States of America - www.nasonline.org/publications/pnas/)
The news correspondents report that additional information may be obtained from S. Eliasof, California Institute of Technology, Pasadena, CA 91125, United States. Additional authors for this research include D. Lazarus, C.G. Peters, R.I. Case, R.O. Cole, J. Hwang, T. Schluep, J. Chao, J. Lin, Y. Yen, H. Han, D.T. Wiley, J.E. Zuckerman and M.E. Davis (see also Clinical Research).
Keywords for this news article include: Pasadena, California, Nanoparticle, United States, Nanotechnology, Clinical Research, Pre-Trial Research, Emerging Technologies, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC